Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects

Trial Profile

Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine (Primary)
  • Indications Opioid-related disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Reckitt Benckiser
  • Most Recent Events

    • 02 Nov 2020 Results of population pharmacokinetics from (NCT01738503, NCT02357901 and NCT02510014) published in the Clinical Pharmacokinetics
    • 22 Feb 2019 Results assessing the effects of a monthly buprenorphine depot subcutaneous injection on QT interval during treatment for opioid use disorder in 1114 subjects pooled from 5 studies (RB-US13-0001, RB-US10-0011, RB-US11-0020, RB-US12-0005, RB-US13-0006) published in the Clinical Pharmacology and Therapeutics
    • 12 Mar 2016 Results (n=89) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top